BellaSeno is an ISO 13485 certified medical technology company founded in 2015. The company is focused on developing novel absorbable 3D printed soft tissue and bone reconstruction implants. In 2022, the company announced two clinical trials in Australia involving its 3D-printed breast and chest implant products. In July 2023, BellaSeno received certification under the European Union Medical Device Regulation, making its custom 3D printed bone and funnel chest scaffolders available for use in Europe.
Professor Philipp Mommsen, senior physician in the management of the Trauma Surgery Clinic at Hannover Medical School, said: "As illustrated by the example of the 46-year-old patient, BellaSeno's stent offers a novel surgical technique that enables the vascularization of the graft by embedding the vascular muscle arc directly into the patient-specific 3D-printed bioabsorbable stent." This technique can be used to treat large bone defects and is a scarce solution for this complex condition."
The stent was designed by BellaSeno as a custom cage to match the patient's anatomy and ensure that the autogenous bone graft (RIA material) is securely secured in the large void.
To achieve proper internal vascularization by positioning the arteriovenous ring or central vessel pedicle during reconstructive surgery, certain design features are included to allow this fragile structure to be placed within the stent.
Dr. Mohit Chhaya, CEO of BellaSeno, said: "This case study once again highlights the versatility of our technology. We can meet almost any design requirement of the healthcare team to optimize the treatment of the patient. The open structure of the scaffold enables vascularization, which is not only essential for proper healing of the bone, but also allows access of immune cells and antimicrobial agents to prevent surgical site infections. We are currently working on next-generation bone scaffolds made of PCL and bioactive glass composites with anti-infection properties."
As this case demonstrates, the intersection of technology, medicine, and personalized care is key to solving some of the most challenging medical conditions. The collaboration between BellaSeno and Hannover Medical School not only brings new life to patients, but also significantly advances the field of bone tissue regeneration, setting a new standard for the treatment of complex bone defects. The stent was designed by BellaSeno as a custom cage to match the patient's anatomy and ensure that the autogenous bone graft (RIA material) is securely secured in the large void.
To achieve proper internal vascularization by positioning the arteriovenous ring or central vessel pedicle during reconstructive surgery, certain design features are included to allow this fragile structure to be placed within the stent.
Dr. Mohit Chhaya, CEO of BellaSeno, said: "This case study once again highlights the versatility of our technology. We can meet almost any design requirement of the healthcare team to optimize the treatment of the patient. The open structure of the scaffold enables vascularization, which is not only essential for proper healing of the bone, but also allows access of immune cells and antimicrobial agents to prevent surgical site infections. We are currently working on next-generation bone scaffolds made of PCL and bioactive glass composites with anti-infection properties."